Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Chris G. Kruse is active.

Publication


Featured researches published by Chris G. Kruse.


Drug Discovery Today | 2005

Keynote review: Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists

Jos H.M. Lange; Chris G. Kruse

The proven clinical efficacy of the CB(1) cannabinoid receptor antagonist rimonabant in both obesity and smoking cessation and its therapeutic potential in other disorders has given a tremendous impetus to the discovery of novel CB(1) antagonists. The number of disclosed patents wherein novel chemical entities having CB(1) antagonistic or inverse agonistic properties have been claimed has exploded. Besides novel compound classes that were identified in screening, rational medicinal chemistry approaches such as conformational constraint and scaffold hopping have been successfully applied. CB(1) receptor modelling has provided insight into crucial receptor-ligand interaction points thereby leading to a general CB(1) inverse agonist pharmacophore model.


Brain | 2010

Concerted changes in transcripts in the prefrontal cortex precede neuropathology in Alzheimer's disease.

Koen Bossers; Kerstin T.S. Wirz; Gideon Meerhoff; Anke H. W. Essing; Jeroen W. van Dongen; Pieter Houba; Chris G. Kruse; Joost Verhaagen; Dick F. Swaab

Using the Braak staging for neurofibrillary changes as an objective indicator of the progression of Alzheimers disease, we have performed a systematic search for global gene expression changes in the prefrontal cortex during the course of Alzheimers disease. In the prefrontal cortex, senile plaques and neurofibrillary changes start to appear around Braak stage III, allowing for the detection of changes in gene expression before, during and after the onset of Alzheimers disease neuropathology. Two distinct patterns of tightly co-regulated groups of genes were observed: (i) an increase in expression in early Braak stages, followed by a decline in expression in later stages (the UPDOWN clusters; containing 865 genes) and (ii) a decrease in expression in early Braak stages, followed by an increase in expression in later stages (the DOWNUP clusters; containing 983 genes). The most profound changes in gene expression were detected between Braak stages II and III, just before or at the onset of plaque pathology and neurofibrillary changes in the prefrontal cortex. We also observed an increase in intracellular beta amyloid staining from Braak stages I to III and a clear decrease in Braak stages IV to VI. These data suggest a link between specific gene expression clusters and Alzheimers disease-associated neuropathology in the prefrontal cortex. Gene ontology over-representation and functional gene network analyses indicate an increase in synaptic activity and changes in plasticity during the very early pre-symptomatic stage of the disease. In later Braak stages, the decreased expression of these genes suggests a reduction in synaptic activity that coincides with the appearance of plaque pathology and neurofibrillary changes and the clinical diagnosis of mild cognitive impairment. The interaction of the ApoE genotype with the expression levels of the genes in the UPDOWN and DOWNUP clusters demonstrates that the accelerating role of ApoE-ε4 in the progression of Alzheimers disease is reflected in the temporal changes in gene expression presented here. Since the UPDOWN cluster contains several genes involved in amyloid precursor protein processing and beta amyloid clearance that increase in expression in parallel with increased intracellular beta amyloid load, just before the onset of plaque pathology in the prefrontal cortex, we hypothesize that the temporally orchestrated increase in genes involved in synaptic activity represents a coping mechanism against increased soluble beta amyloid levels. As these gene expression changes occur before the appearance of Alzheimers disease-associated neuropathology, they provide an excellent starting point for the identification of new targets for the development of therapeutic strategies aimed at the prevention of Alzheimers disease.


Brain Pathology | 2009

Analysis of Gene Expression in Parkinson's Disease : Possible Involvement of Neurotrophic Support and Axon Guidance in Dopaminergic Cell Death

Koen Bossers; Gideon Meerhoff; Rawien Balesar; Jeroen W. van Dongen; Chris G. Kruse; Dick F. Swaab; Joost Verhaagen

Parkinsons disease (PD) is a neurodegenerative disorder characterized by the progressive loss of dopaminergic neurons in the substantia nigra. We have studied alterations in gene expression in the substantia nigra, the caudate nucleus and putamen of four PD patients and four matched controls using custom designed Agilent microarrays. To gain insight into changes in gene expression during early stages of dopaminergic neurodegeneration, we selectively investigated the relatively spared parts of the PD substantia nigra, and correlated gene expression changes with alterations in neuronal density. We identified changes in the expression of 287 transcripts in the substantia nigra, 16 transcripts in the caudate nucleus and four transcripts in the putamen. For selected transcripts, transcriptional alterations were confirmed with qPCR on a larger set of seven PD cases and seven matched controls. We detected concerted changes in functionally connected groups of genes. In the PD substantia nigra, we observed strong evidence for a reduction in neurotrophic support and alterations in axon guidance cues. As the changes occur in relatively spared parts of the PD substantia nigra, they suggest novel disease mechanisms involving neurotrophic support and axon guidance in early stages of cellular stress events, ultimately leading to dopaminergic cell death in PD.


Proceedings of the National Academy of Sciences of the United States of America | 2012

Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors.

Femke S. den Boon; Pascal Chameau; Qiluan Schaafsma-Zhao; Willem van Aken; Monica Bari; Sergio Oddi; Chris G. Kruse; Mauro Maccarrone; Wytse J. Wadman; Taco R. Werkman

The endocannabinoid (eCB) system is widely expressed throughout the central nervous system (CNS) and the functionality of type-1 cannabinoid receptors in neurons is well documented. In contrast, there is little knowledge about type-2 cannabinoid receptors (CB2Rs) in the CNS. Here, we show that CB2Rs are located intracellularly in layer II/III pyramidal cells of the rodent medial prefrontal cortex (mPFC) and that their activation results in IP3R-dependent opening of Ca2+-activated Cl− channels. To investigate the functional role of CB2R activation, we induced neuronal firing and observed a CB2R-mediated reduction in firing frequency. The description of this unique CB2R-mediated signaling pathway, controlling neuronal excitability, broadens our knowledge of the influence of the eCB system on brain function.


Drug Discovery Today | 2012

Target-drug interactions: first principles and their application to drug discovery

Sara Núñez; Jennifer Venhorst; Chris G. Kruse

In this review, we begin by introducing the basic principles of kinetics and thermodynamics of target-drug binding within the context of drug discovery. In addition, we present a meta-analysis of the recent literature describing the kinetic and thermodynamic resolution of successful clinical candidates with diverse mechanisms of action. We finish by discussing the best practices in the triage and chemical optimization towards clinical candidates with maximal in vivo efficacy devoid of adverse events.


Tetrahedron | 1990

Synthesis of optically active silyl protected cyanohydrins

Johannes Brussee; W.T. Loos; Chris G. Kruse; A. Van Der Gen

Abstract Mandelonitrile lyase as present in a crude extract of almond flour has been tested for the synthesis of several chiral cyanohydrins. Silylated cyanohydrins of benzaldehyde, 4-methoxybenzaldehyde, piperonal, 5-methylfurfural, butyraldehyde and crotonaldehyde were obtained in good yield and high enantiomeric excess (93%) after treatment with silyl chlorides and imidazole in DMF.


Tetrahedron Letters | 1996

Solid phase ring-closing metathesis: Cyclization/cleavage approach towards a seven membered cycloolefin

Jan H. van Maarseveen; Jack A. J. den Hartog; Victor Engelen; Emil Finner; Geb M. Visser; Chris G. Kruse

Abstract The application of solid phase ring-closing metathesis (RCM) in a cyclization/cleavage strategy was demonstrated for the first time by the successful synthesis of the seven membered cycloolefin 4 . Probably due to intermolecular metathetical dimerizations at the resin, 4 could not be obtained in higher yields than 54%.


European Neuropsychopharmacology | 2001

Early amygdala damage in the rat as a model for neurodevelopmental psychopathological disorders.

Gerrit Wolterink; Lisette E.W.P.M. Daenen; Suzanne Dubbeldam; M.A.F.M. Gerrits; Rozemarijn S. van Rijn; Chris G. Kruse; Jan A.M. Van Der Heijden; Jan M. van Ree

Neurodevelopmental disorders in medial temporal lobe structures may underlie psychopathological diseases such as schizophrenia and autism. To construct an animal model for these developmental disorders, social and non-social behavioural responses were assessed in rats with ibotenic acid lesions of the (baso-)lateral and central amygdala or ventral hippocampus, induced early in life. Lesioning the amygdala on day 7 after birth resulted in a variety of behavioural disturbances later in life, whereas after similar lesions on day 21 after birth no disturbances developed, except for deficits in social behaviours. Lesioning the hippocampus led to much less disturbances. The results show that amygdala and hippocampus damage at a specific point early in life results in enduring behavioural disturbances that become more manifest after puberty. In particular, lesions of the amygdala on day 7 of life may serve as a rat model with face and construct validity for neurodevelopmental disorders in studying psychopathology.


European Neuropsychopharmacology | 2003

Neonatal lesions in the amygdala or ventral hippocampus disrupt prepulse inhibition of the acoustic startle response; implications for an animal model of neurodevelopmental disorders like schizophrenia

E.W.P.M. Daenen; Gerrit Wolterink; Jan van der Heyden; Chris G. Kruse; Jan M. van Ree

Prepulse inhibition of the acoustic startle response is a behavioural tool applied to assess sensorimotor gating processes in humans and rats. Schizophrenic patients show deficits in prepulse inhibition of the acoustic startle response. The animal model of neurodevelopmental disorders such as schizophrenia, as purported in earlier reports and the present study, is based on the assumption that damage to brain structures early in life (on day 7) disrupts brain maturation of structures connected to the damaged areas, measurable by behavioural changes, whereas similar damage later in life (on day 21) does not result in these behavioural changes. Locomotor activity, the acoustic startle response and its prepulse inhibition were investigated in adult rats lesioned in the amygdala or ventral hippocampus on day 7 or 21 of life. The acoustic startle response was increased in animals lesioned in the amygdala on day 7 or 21 of life, but not in animals lesioned in the ventral hippocampus. Prepulse inhibition was impaired and locomotor activity enhanced in animals lesioned in the amygdala or ventral hippocampus on day 7, but not in animals lesioned in these structures on day 21 of life. The results on the acoustic startle response are suggestive of amygdaloid influences on modulation of the acoustic startle response. The effects of early postnatal lesions on prepulse inhibition and locomotor activity are in support of the animal model of neurodevelopmental disorders like schizophrenia.


Tetrahedron | 1990

Synthesis of optically active ethanolamines.

Johannes Brussee; F. Dofferhoff; Chris G. Kruse; A. Van Der Gen

Abstract (1 R ,2 S )-2-amino-1-arylethanols of high optical purity have been obtained from optically active tert -butyldimethylsilyl protected cyanohydrins by a Grignard reaction, directly followed by reduction of the intermediate imine. Chiral induction gave a large preponderance of the erythro isomers.

Collaboration


Dive into the Chris G. Kruse's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hans W. Scheeren

Radboud University Nijmegen

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge